FDA gives ocrelizumab breakthrough designation for PPMS -Roche

ZURICH, Feb 17 (Reuters) - The U.S. Food and Drug Administration has granted breakthrough therapy designation for ocrelizumab (OCREVUSTM) for treating people with primary progressive multiple sclerosis (PPMS), Roche Holding said on Wednesday.











Read more